Answers are grounded in this paper and cite their sources.
This letter reports the seroprevalence of antibody to human T-lymphotropic virus type III (HTLV-III) among New York City drug detoxification patients without acquired immunodeficiency syndrome (AIDS). Serum specimens were collected from 86 intravenous drug users in May-June 1984 84% of whom reported daily drug use. In addition serum from 17 intravenous drug users who had been diagnosed as having AIDS was collected. Controls were 70 healthy employees from the Centers for Disease Control. The prevalence of anti-HTLV-III among drug abusers without AIDS was 87% (75 subjects) when the enzyme-linked immunosorbent assay (ELISA) was used and 58% (50 subjects) according to radioimmunoprecipitation assay (RIPA). Among drug abusers with AIDS seroprevalence was noted in 65% (11 subjects) by the ELISA method and in 29% (5 subjects) by RIPA. Finally only 2 controls (3%) were seropositive according to the ELISA test; no controls showed reactivity by RIPA. Seropositive non-AIDS intravenous drug abusers from this series are being followed to determine which will acquire immunosuppression-related disease. It is noted that drug users in detoxification programs are not representative of all intravenous drug users. Such a sample is biased toward recent intensive care and possibly toward the presence of other health problems. However this is not a small subpopulation; over 4000 persons/year enter inpatient detoxification programs in New York City.
No takes yet. Share an insight, caveat, or question.
Spira et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: